Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,392 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
Mamishin K, Naito Y, Nomura S, Ogawa G, Niguma K, Baba K, Sakaeda S, Nakajima H, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Kawasaki T, Mukohara T. Mamishin K, et al. Among authors: nakajima h. Anticancer Res. 2021 Dec;41(12):6217-6224. doi: 10.21873/anticanres.15441. Anticancer Res. 2021. PMID: 34848476
The impact of the COVID-19 pandemic on perioperative chemotherapy for breast cancer.
Baba K, Kawamoto M, Mamishin K, Uematsu M, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakajima H, Funasaka C, Nakao T, Kondoh C, Harano K, Matsubara N, Naito Y, Hosono A, Kawasaki T, Mukohara T. Baba K, et al. Among authors: nakajima h. Cancer Med. 2023 Jun;12(11):12095-12105. doi: 10.1002/cam4.5898. Epub 2023 Apr 3. Cancer Med. 2023. PMID: 37012214 Free PMC article.
Safety of immune checkpoint inhibitors after proton beam therapy in head and neck mucosal melanoma: a case series.
Uematsu M, Nakajima H, Hosono A, Kiyohara H, Hirota A, Takahashi N, Fukuda M, Kusuhara S, Nakao T, Funasaka C, Kondoh C, Harano K, Matsubara N, Naito Y, Akimoto T, Mukohara T. Uematsu M, et al. Among authors: nakajima h. Melanoma Res. 2023 Dec 1;33(6):547-552. doi: 10.1097/CMR.0000000000000924. Epub 2023 Sep 4. Melanoma Res. 2023. PMID: 37696254
Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy.
Nakamura Y, Okamoto W, Denda T, Nishina T, Komatsu Y, Yuki S, Yasui H, Esaki T, Sunakawa Y, Ueno M, Shinozaki E, Matsuhashi N, Ohta T, Kato K, Ohtsubo K, Bando H, Hara H, Satoh T, Yamazaki K, Yamamoto Y, Okano N, Terazawa T, Kato T, Oki E, Tsuji A, Horita Y, Hamamoto Y, Kawazoe A, Nakajima H, Nomura S, Mitani R, Yuasa M, Akagi K, Yoshino T. Nakamura Y, et al. Among authors: nakajima h. JCO Precis Oncol. 2022 Feb;6:e2100383. doi: 10.1200/PO.21.00383. JCO Precis Oncol. 2022. PMID: 35188805 Free PMC article.
REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer.
Nakajima H, Kotani D, Bando H, Kato T, Oki E, Shinozaki E, Sunakawa Y, Yamazaki K, Yuki S, Nakamura Y, Yamanaka T, Yoshino T, Ohta T, Taniguchi H, Kagawa Y. Nakajima H, et al. BMC Cancer. 2021 Jun 7;21(1):674. doi: 10.1186/s12885-021-08395-2. BMC Cancer. 2021. PMID: 34098908 Free PMC article.
4,392 results